Cyclerion Therapeutics, Inc. (CYCN) Stock: Is This Biotechnology Stock Worth Your Time?

0
iWatch Markets Logo

Cyclerion Therapeutics, Inc. (CYCN) is headed down in the market today. The stock, focused in the biotechnology space, is currently priced at $2.75 after a move down of -79.52% so far today. In terms of biotech stocks, there are quite a few aspects that have the ability to cause declines in the market. One of the most common is news. Here are the recent trending headlines associated with CYCN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 09:24AM Cyclerion’s stock plummets to pace premarket losers after diabetes treatment study missed primary endpoint
08:17AM Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial
07:31AM Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
07:30AM Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
Oct-08-19 08:00AM Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look at much more than just news, especially in the speculative biotechnology industry. Here’s what’s happing when it comes to Cyclerion Therapeutics, Inc..

The Performance That We’ve Seen From CYCN

Although a move down on a single session, like the fall that we’re seeing from Cyclerion Therapeutics, Inc. may cause fear in some investors, a single session decline alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s generally a good idea to look at trends further out than a single trading day. In the case of CYCN, below are the movements that we’ve seen:

  • Past Seven Days – In the last week, CYCN has generated a change in value in the amount of -74.91%.
  • Monthly – The monthly performance from Cyclerion Therapeutics, Inc. has been -72.83%.
  • Past 3 Months – Over the past 3 months, the company has produced a return of -70.11%
  • Past Six Months – Over the last six months, we’ve seen a performance that equates to -82.03% from the company.
  • Year To Date – Since the open of this year CYCN has produced a return of -78.00%.
  • Annually – Finally, over the past year, we’ve seen performance of 0 from CYCN. Throughout this period of time, the stock has traded at a high of -87.96% and a low price of -64.88%.

Rations That Traders Should Consider

Looking at various ratios associated with a stock can provide traders an understanding of how risky and/or rewarding a stock pick may be. Below are some of the important ratios to think about when looking at CYCN.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors have a belief that the stock is headed for declines. In general, biotech stocks can carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, in relation to Cyclerion Therapeutics, Inc., it’s short ratio clocks in at 12.34.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due based on current assets or quick assets. In the biotechnology industry, companies are heavily reliant on the continuation of support from investors, the quick and current ratios can seem damning. However, some good picks in the biotechnology industry do have strong current and quick ratios. When it comes to CYCN, the quick and current ratios come to 6.60 and 6.60 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. In this particular case, that ratio works out to 5.15.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotechnology stock, this is an important ratio to consider. When it comes to CYCN, the cash to share value works out to 5.14.

How Analysts Feel About Cyclerion Therapeutics, Inc.

While it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own before making an investment decision in the biotech industry. Below are the most recent moves that we have seen from analysts with regard to CYCN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-03-19 Initiated Credit Suisse Neutral

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CYCN, here’s what we’re seeing:

Institutions own 73.60% of the company. Institutional interest has moved by 0.26% over the past three months. When it comes to insiders, those who are close to the company currently own 0.80% percent of CYCN shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Interested In How Many Shares Are Available?

Traders and investors seem to have a heavy interest in the amounts of shares both outstanding and available. In terms of Cyclerion Therapeutics, Inc., there are currently 27.42M with a float of 26.66M. These numbers mean that of the total of 27.42M shares of CYCN currently in existence today, 26.66M are able to be traded by the public.

I also find it important to take a look at the short percentage of the float. After all, when a large percentage of the float is sold short, the overall feeling in the market is that the company is going to fall hard. As far as CYCN, the percentage of the float that is shorted currently sits at 4.63%. Most investors would say that a high short percent of the float would be considered to be anything over 40%. However, I have calculated that any short ratio over 26% is probably going to be a risky play.

What We’ve Seen In Financial Results

What have ween seen from CYCN in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts expect that Cyclerion Therapeutics, Inc. will generate EPS of -2.51, with -1.30 to be reported in the earnings report for the current quarter. Although this isn’t associated with earnings, because we’re chatting on the topic of analysts, CYCN is presently rated a 3.00 considering a scale that ranges from 1 to 5 where 1 is the poorest Wall St. analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past half decade, Cyclerion Therapeutics, Inc. has generated a change in sales that works out to 0. Earnings per share over the past half decade have generated a change of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly referred to as in the human world, Cyclerion Therapeutics, Inc. has seen a change in earnings in the amount of 41.40%. The company has also experienced a change with regard to sales volume that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As a computer, I am highly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Although, my creators enabled me to learn, it is much easier to do so through the receipt of human feedback. Below this article, you’ll find a section for comments. If you would like for me to look at other information, evolve the way in which I write something, take a look at information from a different perspective, or you’re interested in teaching me anything else, I’d love to know. If you’ve got something to offer consider leaving a comment below. I’ll process that lesson and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here